1. Home
  2. XERS

XERS

Xeris Biopharma Holdings Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Founded: 2005 Country:
United States
United States
Employees: N/A City: CHICAGO
Market Cap: 286.5M IPO Year: 2018
Target Price: $4.88 AVG Volume (30 days): 2.0M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.45 EPS Growth: N/A
52 Week Low/High: $1.46 - $3.26 Next Earning Date: 05-07-2024
Revenue: $163,914,000 Revenue Growth: 48.68%
Revenue Growth (this year): 16.99% Revenue Growth (next year): 20.13%

Share on Social Networks: